EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Comparisons

How should clinics compare 503A and 503B GLP-1 compounding?

Dose Diligence research deskSection 03 · Page 6 of 12Last updated 17 Nov 2026

Treat 503A and 503B as distinct legal frameworks, not supplier quality tiers or interchangeable routes to lower prices.

QuestionSection 503ASection 503B
Patient-specific prescription?Generally centres on an identified individual patient and a valid prescription, with conditions governing limited anticipatory compoundingAn outsourcing facility may or may not obtain prescriptions for identified individual patients
General office stock?A patient-specific prescription route should not be presented as general office-stock permissionCan support qualifying office-stock arrangements, subject to all applicable conditions
Manufacturing standard?Qualifying products are exempt from federal current good manufacturing practice requirements; that does not remove other quality obligationsNot exempt from current good manufacturing practice requirements
Copying restriction?Restrictions on regularly or inordinately compounding essentially copies of commercially available productsSeparate restriction on preparations that are essentially copies of approved drugs
Raw-ingredient question?Assess the applicable bulk-substance conditions and exact ingredientBulk-substance eligibility is an independent gate; a prescription does not remove it
Buyer evidence?Prescription process, actual formulation, relevant prescriber determination and pharmacy quality evidenceExact facility, registration and inspection history, preparation-specific basis, quality systems and supply chain

These distinctions are supported by FDA's framework and the 503B statute. Neither route produces an FDA-approved compounded medicine. (fda.gov)

Does a patient-specific prescription or added B12 make compounding permissible?

Neither is an automatic exemption. FDA's 503A guidance explains that a prescriber determination must identify a formulation change producing a significant difference for the individual patient; merely identifying the patient and formulation is insufficient for that determination. Lower price alone is not sufficient. (fda.gov)

FDA's semaglutide with vitamin B12 can still meet its essentially-copy criteria. A supplier's standard additive should therefore trigger questions, not close the legal review. (fda.gov)

For a proposed exception, request:

  • The exact active ingredient, formulation, concentration, dosage form and source.
  • The applicable statutory pathway and product-specific legal analysis.
  • The clinician's independent assessment and documentation where relevant.
  • The compounding and dispensing facilities—not just the marketing company.
  • Quality, labelling, beyond-use and post-opening instructions.
  • Destination-state permissions and a transition plan if the arrangement stops.

FDA identifies semaglutide sodium and semaglutide acetate as different active ingredients from that used in approved products and says it is unaware of a lawful basis for their use in compounding. Do not accept a generic statement that the ingredient is simply semaglutide. (fda.gov)

Can a broker resell 503B products to a clinic?

Do not assume an ordinary wholesale resale model is permissible. Section 503B includes a prohibition on sale or transfer by an entity other than the outsourcing facility that compounded the drug, with specified treatment-setting administration and prescription-dispensing provisions. Have counsel map the actual title, payment and transfer chain. (govinfo.gov)

Explore the table row by row

A working view of the research

Patient-specific prescription?

Section 503A
Generally centres on an identified individual patient and a valid prescription, with conditions governing limited anticipatory compounding
Section 503B
An outsourcing facility may or may not obtain prescriptions for identified individual patients

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/media/162166/download?utm_source=openai
  2. fda.gov · Source 2 ↗https://www.fda.gov/media/98973/download?attachment=&os=apprefDapp
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  4. fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss?ftag=YHF4eb9d17
  5. govinfo.gov · Source 5 ↗https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353b.htm
Section sources →